Robert Pickering - Hikma Pharmaceuticals Senior Non-Executive Independent Director
| HKMPF Stock | USD 22.33 1.92 7.92% |
Director
Mr. Robert M. Pickering is Senior NonExecutive Independent Director of Hikma Pharmaceuticals Plc. Robert became Senior Independent Director in May 2014. Robert was Chief Executive of Cazenove Group PLC and subsequently JP Morgan Cazenove until 2008. During 23 years at Cazenove and Co. he acquired extensive experience of the corporate and investment environment. Qualified solicitor with a law degree from Lincoln College, Oxford. since 2014.
| Age | 57 |
| Tenure | 10 years |
| Phone | 44 20 7399 2760 |
| Web | https://www.hikma.com |
Hikma Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.077 % which means that it generated a profit of $0.077 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.154 %, meaning that it generated $0.154 on every $100 dollars invested by stockholders. Hikma Pharmaceuticals' management efficiency ratios could be used to measure how well Hikma Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Willard Dere | Mersana Therapeutics | 64 | |
| Eduardo Szymanski | Betterware De Mexico | N/A | |
| Arthur Sullivan | Provident Bancorp | N/A | |
| Andres Chevallier | Betterware De Mexico | 40 | |
| Eliahu Zamir | Formula Systems 1985 | 47 | |
| Clyde Patterson | Home Federal Bancorp | 74 | |
| Walter Colquitt | Home Federal Bancorp | 72 | |
| Dafna Cohen | Formula Systems 1985 | 45 | |
| Andrew Hack | Mersana Therapeutics | 43 | |
| Richard Peeke | Provident Bancorp | 69 | |
| John Bosen | Provident Bancorp | 49 | |
| Thomas Trawick | Home Federal Bancorp | 48 | |
| Frederic MD | Immutep Ltd ADR | 69 | |
| Scott Lawrence | Home Federal Bancorp | 71 | |
| Kristen Hege | Mersana Therapeutics | 54 | |
| Laurie Knapp | Provident Bancorp | 56 | |
| Wayne Tatro | Provident Bancorp | 72 | |
| Pete Meyers | Immutep Ltd ADR | 46 | |
| Jay Gould | Provident Bancorp | N/A | |
| Russell Howard | Immutep Ltd ADR | 64 | |
| Iris Yahal | Formula Systems 1985 | 53 | |
Management Performance
| Return On Equity | 0.15 | |||
| Return On Asset | 0.077 |
Hikma Pharmaceuticals PLC Leadership Team
Elected by the shareholders, the Hikma Pharmaceuticals' board of directors comprises two types of representatives: Hikma Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hikma. The board's role is to monitor Hikma Pharmaceuticals' management team and ensure that shareholders' interests are well served. Hikma Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hikma Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Fadi Nassar, Corporate Vice President - Active Pharmaceutical Ingredients | ||
| Bassam Kanaan, Chief Strategy & Corporate Development Officer | ||
| Khalid Nabilsi, Chief Officer | ||
| Hussein Arkhagha, General Counsel | ||
| Susan Ringdal, Vice President - Corporate Strategy and Investor Relations | ||
| Pamela Kirby, Non-Executive Independent Director | ||
| John Castellani, Non-Executive Independent Director | ||
| Brian Hoffman, President and Chief Executive of - Generics Division | ||
| Ali AlHusry, Non-Executive Director | ||
| Jochen Gann, Non-Executive Director | ||
| Engineer Darwazah, Ex CEO | ||
| Peter Speirs, Company Secretary | ||
| Patrick Butler, Non-Executive Independent Director | ||
| Brian Hoffmann, Pres Generics | ||
| Said Darwazah, Chairman and CEO | ||
| Michael Raya, President and CEO, USA | ||
| Samuel Park, Global US | ||
| Ronald Goode, Non-Executive Independent Director | ||
| Bryan Hotston, CIO | ||
| Sigurdur Olafsson, CEO | ||
| Breffni Byrne, Non-Executive Independent Director | ||
| Nina Henderson, Non-Executive Independent Director | ||
| Cynthia Schwalm, Independent Non-Executive Director | ||
| Ragheb AlShakhshir, Corporate Vice President - Research & Development | ||
| Michael Ashton, Non-Executive Independent Director | ||
| Majda Labadi, Corporate Vice President - Human Resources | ||
| Ibrahim Jalal, Sr. Corporate VP of Technical Affairs | ||
| Riad Mishlawi, EU Vice President and Global Head - Injectables | ||
| Robert Pickering, Senior Non-Executive Independent Director | ||
| Mazen Darwazah, Executive Vice Chairman, Member of Compliance, Responsibility and Ethics Committee, Member of Nomination Committee, CEO of MENA and Emerging Markets and President of MENA and Emerging Markets | ||
| CPA CFA, Exec MA |
Hikma Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Hikma Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.15 | |||
| Return On Asset | 0.077 | |||
| Profit Margin | 0.14 % | |||
| Operating Margin | 0.22 % | |||
| Current Valuation | 5.26 B | |||
| Shares Outstanding | 220.26 M | |||
| Shares Owned By Insiders | 29.67 % | |||
| Shares Owned By Institutions | 41.69 % | |||
| Price To Earning | 7.89 X | |||
| Price To Book | 1.84 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hikma Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for Hikma Pink Sheet analysis
When running Hikma Pharmaceuticals' price analysis, check to measure Hikma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hikma Pharmaceuticals is operating at the current time. Most of Hikma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hikma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hikma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hikma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Commodity Directory Find actively traded commodities issued by global exchanges |